StockData
Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd. (SLGL) company profile

SLGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 19, 2026Score 10/30
$52.83−2.13 (-3.88%)

Close on Nov 17, 2026Market cap $147.19MP/E –Yield –

About Sol-Gel Technologies

Pharmaceutical Preparations, SIC 2834

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on identifying, developing, and commercializing topical therapies for skin conditions. Its commercial portfolio includes Twyneo, an FDA-approved non-antibiotic topical cream for acne vulgaris, and Epsolay, an approved encapsulated benzoyl peroxide cream for papulopustular rosacea. In addition to commercialized treatments, the company is advancing an investigational pipeline that includes SGT-610 (patidegib gel) for preventing basal cell carcinomas in Gorlin syndrome patients and SGT-210 (erlotinib) for localized epidermal growth factor receptor inhibition. Its target customer base consists of patients requiring specialized dermatological medical treatments.

The company maintains its principal executive offices in Ness Ziona, Israel. Commercial distribution and product development are conducted internationally, with active commercialization, licensing, and purchase agreements supporting operations across target territories including the United States, Canada, and China. Research, development, and administrative activities are supported by internal operations and contracted third-party manufacturing organizations.

Summary of the business section of Sol-Gel Technologies's latest annual report, written by StockData.

Company profile

Company

Legal name
Sol-Gel Technologies Ltd.
Founded
1997
Headquarters
Ness Ziona, Israel
Address
7 Golda Meir St., Weizmann Science Park 7403648
Phone
97289313433
Employees
28, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Kesselman & Kesselman, Tel-Aviv, Israel

Stock & identifiers

Ticker
SLGL
Exchange
Nasdaq
IPO date
Feb 2, 2018
Shares outstanding
3M, Dec 31, 2025
Filer category
Non-accelerated filer
Stock splits
1-for-10 reverse, May 5, 2025
SEC CIK
1684693
CUSIP
M8694L137
FIGI
BBG00HLD5HL4
Share class FIGI
BBG00HLD5J94
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Moshe ArkinChairman of Board and CEO, Director1,750,113
Ofer ToledanoVP Research & Dev.1,461
Itzik YosefChief Operating Officer–
Eyal Ben-OrChief Financial Officer1,000
Ofra Levy-HachamVP Clinical, Reg & Quality–
Michael GlezinChief Business Officer1,500
Itai Gidon ArkinDirector–
Ran GottfriedDirector1,550
Sharon KochanDirector–
Yuval YanaiDirector–
Hanna LermanDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 2, 2018
Offer price
$12.00
Exchange
Nasdaq
First trading day
Feb 1, 2018
First-day close
$13.64+13.7%
Lock-up ends (est.)
Jul 31, 2018

“The initial public offering price is $12.00 per ordinary share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 28 employees, all of whom are located”

Corporate history

Events identified from SEC filings

See a number that looks wrong?